7.91
-0.63%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About United Laboratories International Holdings
Its shares trade on HKEX under the ticker 3933.HK. It has been listed since 15 June 2007. In the fiscal year to 31 December 2025, it reported revenue of CN¥15.41bn and net income of CN¥2.43bn. At that date it held total assets of CN¥36.06bn and shareholders' equity of CN¥20.30bn.
United Laboratories International Holdings Ltd. is an investment company, which engages in the research, development, production and operation of medical intermediates, active pharmaceutical ingredients (APIs) and pharmaceutical preparations. The company employs 13,000 full-time employees The company went IPO on 2007-06-15. The firm operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Jun 2007
- Employees
- 13,000
- Website
- tul.com.cn ↗
Leadership
Pay as last reported
- Mr. Hoi Shan TsoiExecutive Chairman of the Board, since 2009CN¥4.2m
- Mr. Wing Hon LeungExecutive Vice Chairman of the Board, Chief Financial Officer, Company Secretary, since 2024CN¥4.2m
- Mr. Yu Ping FangVice President, Executive Director, since 2008CN¥2.5m
- Ms. Su Yan ZhuVice President, Executive DirectorCN¥2.5m
- Ms. Xian Hong ZouVice President, Executive DirectorCN¥2.5m
- Mr. Chun Lai CaoGeneral Manager - United Bio-Technology (Hengqin) Co Limited
- Mr. Shun Teng ZhengOperating Senior General Manager - Groups Intermediate and Bulk Medicine
- Ms. Siu Chit ChoyExecutive DirectorCN¥2.8m
- Ms. Min ChenGeneral Manager - China Sales Division of Finished Products
- Mr. Yu Bo HanGeneral Manager - Zhuhai United Laboratories Company Limited
- Mr. Bing Yang LiuGeneral Manager - Guangdong Kaiping Kingly Capsules Limited
- Mr. Hong Chi LiuGeneral Manager - The United Animal Healthcare (Inner Mongolia) Co Limited
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- United Laboratories International Holdings Ltd has established a strong market presence with its extensive range of high-quality pharmaceutical and healthcare products. This allows the company to enjoy a competitive edge in the industry and attract a large customer base.
- The company offers a diverse range of products, including prescription drugs, over-the-counter medications, medical devices, and consumer healthcare products. This diversification helps United Laboratories International Holdings Ltd to mitigate risks and capture various market segments, thus enhancing its revenue potential.
Weaknesses
- United Laboratories International Holdings Ltd heavily relies on a few key markets for its revenue generation. Any economic or political instability in these specific regions could significantly impact the company's financial performance and growth prospects.
- Despite its strong market presence in certain regions, United Laboratories International Holdings Ltd has limited global reach compared to some of its major competitors. This restricts the company's ability to leverage opportunities in untapped markets and limits its potential for expansion.
Opportunities
- The growing global population, along with the increasing prevalence of diseases and aging demographics, presents significant opportunities for United Laboratories International Holdings Ltd to expand its business. The rising demand for pharmaceutical and healthcare products creates a favorable market environment for the company to explore new markets and introduce innovative solutions.
- Technological advancements, such as digital health solutions and personalized medicine, open up new possibilities for United Laboratories International Holdings Ltd. By investing in research and development, the company can stay at the forefront of these emerging technologies, enhance its product offerings, and improve patient outcomes.
Threats
- The pharmaceutical and healthcare industry is highly competitive, with numerous global and local players vying for market share. This intense competition poses a threat to United Laboratories International Holdings Ltd, as it needs to continuously innovate, market effectively, and differentiate its products to maintain its position in the market.
- Compliance with stringent regulations and changing regulatory environments in different countries can pose challenges for United Laboratories International Holdings Ltd. Adapting to new regulatory requirements and ensuring product safety and efficacy may require additional resources and investments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.